Here are three things to know.
1. The recall applies to EpiPens distributed in Australia, New Zealand, Europe and Japan.
2. Both individuals who tried to use the faulty EpiPens sought treatment through the use of an alternate EpiPen, Mylan said Wednesday in a statement.
3. Mylan said it is working with regulatory authorities to notify them of the recall, according to the report.
More articles on supply chain:
Trump meets with Congressional Black Caucus, promises lower drug costs
Study: Surgeon scorecards reduce supply cost without affecting outcomes
FDA grants tentative approval to Mylan’s HIV/AIDS drug: 3 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
